You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBumetanide
Accession NumberDB00887  (APRD00294)
TypeSmall Molecule
GroupsApproved
DescriptionA sulfamyl diuretic. [PubChem]
Structure
Thumb
Synonyms
3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid
3-Butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
3-Butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
3-Butylamino-4-phenoxy-5-sulfamoylbenzoic acid
Bumetanida
Bumetanidum
External Identifiers
  • a684051
  • CS 380
  • Ro 10-6338
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BumetanideTablet1 mg/1OralParagon Enterprises, Inc2016-11-16Not applicableUs
BumetanideTablet.5 mg/1OralEdenbridge Pharmaceuticals, LLC2015-10-15Not applicableUs
BumetanideTablet1 mg/1OralEdenbridge Pharmaceuticals, LLC2015-10-15Not applicableUs
BumetanideTablet2 mg/1OralEdenbridge Pharmaceuticals, LLC2015-10-15Not applicableUs
BumetanideTablet1 mg/1OralParagon Enterprises, Inc2016-08-09Not applicableUs
Burinex - Tab 2mgTablet2 mgOralLeo Pharma Inc1996-12-312004-07-23Canada
Burinex Tab 1mgTablet1 mgOralLeo Pharma Inc1993-12-31Not applicableCanada
Burinex Tab 5mgTablet5 mgOralLeo Pharma Inc1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BumetanideInjection.25 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
BumetanideInjection.25 mg/mLIntramuscular; IntravenousCardinal Health1995-03-01Not applicableUs
BumetanideTablet1 mg/1OralNu Care Pharmaceuticals, Inc.2007-10-16Not applicableUs
BumetanideTablet.5 mg/1OralTeva Pharmaceuticals USA Inc2007-10-16Not applicableUs
BumetanideTablet1 mg/1OralAv Kare, Inc.2015-01-26Not applicableUs
BumetanideTablet1 mg/1Oralbryant ranch prepack2007-10-16Not applicableUs
BumetanideTablet1 mg/1OralEon Labs, Inc.1996-11-21Not applicableUs
BumetanideTablet2 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-10-16Not applicableUs
BumetanideInjection, solution.25 mg/mLIntramuscular; IntravenousCardinal Health2011-11-16Not applicableUs
BumetanideTablet.5 mg/1OralCarilion Materials Management2007-10-16Not applicableUs
BumetanideTablet1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-16Not applicableUs
BumetanideTablet1 mg/1OralPhysicians Total Care, Inc.2009-02-16Not applicableUs
BumetanideTablet1 mg/1OralUnit Dose Services1996-11-21Not applicableUs
BumetanideInjection.25 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
BumetanideInjection.25 mg/mLIntramuscular; IntravenousCardinal Health2009-01-27Not applicableUs
BumetanideTablet1 mg/1OralAvera Mc Kennan Hospital2015-03-26Not applicableUs
BumetanideTablet1 mg/1OralTeva Pharmaceuticals USA Inc2007-10-16Not applicableUs
BumetanideTablet2 mg/1OralAv Kare, Inc.2015-01-26Not applicableUs
BumetanideTablet2 mg/1OralEon Labs, Inc.1996-11-21Not applicableUs
BumetanideTablet1 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-10-16Not applicableUs
BumetanideTablet1 mg/1OralCardinal Health2011-04-29Not applicableUs
BumetanideTablet1 mg/1OralCarilion Materials Management1996-11-21Not applicableUs
BumetanideTablet2 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-16Not applicableUs
BumetanideTablet.5 mg/1OralPhysicians Total Care, Inc.2000-11-29Not applicableUs
BumetanideTablet2 mg/1OralUnit Dose Services1996-11-21Not applicableUs
BumetanideInjection.25 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
BumetanideInjection, solution.25 mg/mLIntramuscular; IntravenousCardinal Health2011-11-16Not applicableUs
BumetanideTablet2 mg/1OralAvera Mc Kennan Hospital2015-03-13Not applicableUs
BumetanideTablet2 mg/1OralTeva Pharmaceuticals USA Inc2007-10-16Not applicableUs
BumetanideTablet1 mg/1OralUnit Dose Services2007-10-16Not applicableUs
BumetanideTablet.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-10-16Not applicableUs
BumetanideTablet1 mg/1OralSt Marys Medical Park Pharmacy2014-05-22Not applicableUs
BumetanideTablet2 mg/1OralAvera Mc Kennan Hospital2015-09-11Not applicableUs
BumetanideInjection.25 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2008-04-30Not applicableUs
BumetanideTablet2 mg/1OralPhysicians Total Care, Inc.2006-12-13Not applicableUs
BumetanideTablet.5 mg/1OralEon Labs, Inc.1996-11-21Not applicableUs
BumetanideTablet1 mg/1OralAidarex Pharmaceuticals LLC2007-10-16Not applicableUs
BumetanideInjection, solution.25 mg/mLIntravenousCardinal Health2011-11-16Not applicableUs
BumetanideTablet1 mg/1OralAvera Mc Kennan Hospital2015-09-28Not applicableUs
BumetanideInjection, solution.25 mg/mLIntramuscular; IntravenousHospira, Inc.1994-10-31Not applicableUs
BumetanideTablet2 mg/1OralUnit Dose Services2007-10-16Not applicableUs
BumetanideTablet2 mg/1OralSt Marys Medical Park Pharmacy2014-08-20Not applicableUs
BumetanideTablet.5 mg/1OralAv Kare, Inc.2015-01-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BumexF. Hoffmann-La Roche Ltd.
BurinexF. Hoffmann-La Roche Ltd.
FordiuranLEO Pharma A/S
LunetoronDaiichi Sankyo
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0Y2S3XUQ5H
CAS number28395-03-1
WeightAverage: 364.416
Monoisotopic: 364.10929245
Chemical FormulaC17H20N2O5S
InChI KeyMAEIEVLCKWDQJH-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
IUPAC Name
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
SMILES
CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O
Pharmacology
IndicationFor the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.
Structured Indications
PharmacodynamicsBumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect. Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).
Mechanism of actionBumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis.
TargetKindPharmacological actionActionsOrganismUniProt ID
Solute carrier family 12 member 1Proteinyes
inhibitor
HumanQ13621 details
Solute carrier family 12 member 2Proteinyes
inhibitor
HumanP55011 details
Solute carrier family 12 member 4Proteinyes
inhibitor
HumanQ9UP95 details
Solute carrier family 12 member 5Proteinyes
inhibitor
HumanQ9H2X9 details
Cystic fibrosis transmembrane conductance regulatorProteinunknown
antagonist
HumanP13569 details
Related Articles
AbsorptionBumetanide is completely absorbed (80%), and the absorption is not altered when taken with food. Bioavailability is almost complete.
Volume of distributionNot Available
Protein binding97%
Metabolism

45% is secreted unchanged. Urinary and biliary metabolites are formed by oxidation of the N-butyl side chain.

Route of eliminationOral administration of carbon-14 labeled Bumex to human volunteers revealed that 81% of the administered radioactivity was excreted in the urine, 45% of it as unchanged drug. Biliary excretion of Bumex amounted to only 2% of the administered dose.
Half life60-90 minutes
Clearance
  • 0.2 – 1.1 mL/min/kg [preterm and full-term neonates with respiratory disorders]
  • 2.17 mL/min/kg [neonates receiving bumetanide for volume overload]
  • 1.8 +/- 0.3 mL/min/kg [geriatric subjects]
  • 2.9 +/- 0.2 mL/min/kg [younger subjects]
ToxicityOverdosage can lead to acute profound water loss, volume and electrolyte depletion, dehydration, reduction of blood volume and circulatory collapse with a possibility of vascular thrombosis and embolism. Electrolyte depletion may be manifested by weakness, dizziness, mental confusion, anorexia, lethargy, vomiting and cramps. Treatment consists of replacement of fluid and electrolyte losses by careful monitoring of the urine and electrolyte output and serum electrolyte levels.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bumetanide Action PathwayDrug actionSMP00088
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Bumetanide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Bumetanide.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Bumetanide.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Bumetanide.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Bumetanide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the diuretic activities of Bumetanide.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Bumetanide.Withdrawn
AcetovanilloneAcetovanillone may decrease the diuretic activities of Bumetanide.Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Bumetanide.Approved, Vet Approved
AclarubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Aclarubicin.Investigational
AdapaleneAdapalene may decrease the diuretic activities of Bumetanide.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Bumetanide.Experimental
AlclometasoneAlclometasone may increase the hypokalemic activities of Bumetanide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bumetanide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Bumetanide.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Bumetanide.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Bumetanide is combined with Aliskiren.Approved, Investigational
AllopurinolThe risk or severity of adverse effects can be increased when Bumetanide is combined with Allopurinol.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Bumetanide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Bumetanide.Experimental, Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Bumetanide.Approved
AmifostineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amifostine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amikacin.Approved, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Bumetanide.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Bumetanide.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bumetanide.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Bumetanide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amphotericin B.Approved, Investigational
AmrubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amrubicin.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amyl Nitrite.Approved
AnecortaveAnecortave may increase the hypokalemic activities of Bumetanide.Investigational
AnisodamineAnisodamine may decrease the diuretic activities of Bumetanide.Investigational
annamycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with annamycin.Investigational
AntipyrineAntipyrine may decrease the diuretic activities of Bumetanide.Approved
AnvirzelThe risk or severity of adverse effects can be increased when Bumetanide is combined with Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Apraclonidine.Approved
ApramycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Apramycin.Experimental, Vet Approved
ApremilastApremilast may decrease the diuretic activities of Bumetanide.Approved, Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Arbekacin.Approved
ArbutamineArbutamine may increase the hypokalemic activities of Bumetanide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Bumetanide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Bumetanide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Bumetanide.Approved
Atracurium besylateBumetanide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the diuretic activities of Bumetanide.Withdrawn
AzelastineAzelastine may decrease the diuretic activities of Bumetanide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bumetanide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Bumetanide.Investigational
BalsalazideBalsalazide may decrease the diuretic activities of Bumetanide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Bumetanide.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Bumetanide.Experimental
BarbitalBarbital may increase the hypotensive activities of Bumetanide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Barnidipine.Approved
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Bumetanide.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Bumetanide.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Bumetanide.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bumetanide.Approved
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Bumetanide.Withdrawn
BepridilThe risk or severity of adverse effects can be increased when Bumetanide is combined with Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bumetanide.Approved
Betulinic AcidBetulinic Acid may decrease the diuretic activities of Bumetanide.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Bumetanide.Experimental, Illicit, Withdrawn
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Bumetanide.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bumetanide is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bumetanide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Bumetanide.Approved
BromfenacBromfenac may decrease the diuretic activities of Bumetanide.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may decrease the diuretic activities of Bumetanide.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Bumetanide.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Bumetanide.Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Bupivacaine.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Bumetanide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bumetanide.Approved, Illicit, Vet Approved
CanagliflozinCanagliflozin may increase the hypotensive activities of Bumetanide.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Bumetanide.Approved
CandoxatrilBumetanide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Bumetanide is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Bumetanide.Illicit, Vet Approved
CarprofenCarprofen may decrease the diuretic activities of Bumetanide.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Bumetanide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Bumetanide is combined with Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the diuretic activities of Bumetanide.Experimental
CelecoxibCelecoxib may decrease the diuretic activities of Bumetanide.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Bumetanide.Approved, Investigational
ChloroquineChloroquine may decrease the diuretic activities of Bumetanide.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bumetanide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Bumetanide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bumetanide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Bumetanide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Bumetanide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Bumetanide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Cilnidipine.Approved
Cisatracurium besylateBumetanide may decrease the neuromuscular blocking activities of Cisatracurium besylate.Approved
CisplatinBumetanide may increase the nephrotoxic activities of Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Bumetanide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Bumetanide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Bumetanide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Bumetanide.Approved
ClonixinClonixin may decrease the diuretic activities of Bumetanide.Approved
ClozapineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Bumetanide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Bumetanide is combined with Conivaptan.Approved, Investigational
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Bumetanide.Approved
CurcuminCurcumin may decrease the diuretic activities of Bumetanide.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bumetanide.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the diuretic activities of Bumetanide.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dapagliflozin.Approved
DaunorubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Daunorubicin.Approved
DecamethoniumBumetanide may decrease the neuromuscular blocking activities of Decamethonium.Approved
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Bumetanide.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Bumetanide.Investigational
dersalazinedersalazine may decrease the diuretic activities of Bumetanide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Bumetanide is combined with Desflurane.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside.Approved
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Bumetanide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Bumetanide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Bumetanide.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Bumetanide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Bumetanide.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bumetanide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bumetanide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Bumetanide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bumetanide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Bumetanide.Approved
DiclofenacDiclofenac may decrease the diuretic activities of Bumetanide.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Diclofenamide.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Bumetanide.Approved
DiflunisalDiflunisal may decrease the diuretic activities of Bumetanide.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Bumetanide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Bumetanide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Bumetanide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Bumetanide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Bumetanide.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dihydrostreptomycin.Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Bumetanide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bumetanide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Bumetanide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Bumetanide.Approved
DofetilideBumetanide may increase the QTc-prolonging activities of Dofetilide.Approved
Domoic AcidBumetanide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chlorideBumetanide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Bumetanide.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Doxorubicin.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Bumetanide.Investigational
DroxicamDroxicam may decrease the diuretic activities of Bumetanide.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Bumetanide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Bumetanide.Approved
DuloxetineBumetanide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the diuretic activities of Bumetanide.Investigational
E6201E6201 may decrease the diuretic activities of Bumetanide.Investigational
EbselenEbselen may decrease the diuretic activities of Bumetanide.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Bumetanide.Approved, Vet Approved
EnalaprilatBumetanide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Bumetanide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
EpirizoleEpirizole may decrease the diuretic activities of Bumetanide.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Epirubicin.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Bumetanide.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Bumetanide is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bumetanide.Approved
EquileninEquilenin may increase the hypokalemic activities of Bumetanide.Experimental
EquilinEquilin may increase the hypokalemic activities of Bumetanide.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bumetanide.Approved
EstroneEstrone may increase the hypokalemic activities of Bumetanide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Bumetanide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Bumetanide is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the diuretic activities of Bumetanide.Approved, Investigational
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Bumetanide.Approved, Illicit
EtodolacEtodolac may decrease the diuretic activities of Bumetanide.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the diuretic activities of Bumetanide.Approved
EtoricoxibEtoricoxib may decrease the diuretic activities of Bumetanide.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Bumetanide.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Bumetanide.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Bumetanide.Approved, Investigational
exisulindexisulind may decrease the diuretic activities of Bumetanide.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the diuretic activities of Bumetanide.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Bumetanide is combined with Fenoldopam.Approved
FenoprofenFenoprofen may decrease the diuretic activities of Bumetanide.Approved
FenoterolFenoterol may increase the hypokalemic activities of Bumetanide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bumetanide.Approved, Illicit, Investigational, Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Bumetanide is combined with Fimasartan.Approved
FloctafenineFloctafenine may decrease the diuretic activities of Bumetanide.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Bumetanide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Bumetanide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Bumetanide.Approved, Investigational
FlunixinFlunixin may decrease the diuretic activities of Bumetanide.Vet Approved
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Bumetanide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Bumetanide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Bumetanide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Bumetanide.Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Bumetanide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Bumetanide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Bumetanide.Approved
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Bumetanide.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Bumetanide.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Bumetanide.Approved
FormestaneFormestane may increase the hypokalemic activities of Bumetanide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Bumetanide.Approved, Investigational
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Bumetanide.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bumetanide.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Bumetanide.Approved
FramycetinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Framycetin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Bumetanide.Approved, Vet Approved
Gallamine TriethiodideBumetanide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Bumetanide is combined with GENTAMICIN C1A.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Bumetanide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Bumetanide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Bumetanide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Bumetanide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Bumetanide.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Bumetanide.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Bumetanide.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Bumetanide is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Bumetanide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Bumetanide.Approved, Illicit
HexobarbitalHexobarbital may increase the hypotensive activities of Bumetanide.Approved
HigenamineHigenamine may decrease the diuretic activities of Bumetanide.Investigational
HMPL-004HMPL-004 may decrease the diuretic activities of Bumetanide.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Bumetanide.Approved, Illicit
Hygromycin BThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hygromycin B.Vet Approved
IbuprofenIbuprofen may decrease the diuretic activities of Bumetanide.Approved
IbuproxamIbuproxam may decrease the diuretic activities of Bumetanide.Withdrawn
IcatibantIcatibant may decrease the diuretic activities of Bumetanide.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Idarubicin.Approved
IloprostThe risk or severity of adverse effects can be increased when Bumetanide is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Bumetanide is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Bumetanide.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Bumetanide.Approved
IndomethacinIndomethacin may decrease the diuretic activities of Bumetanide.Approved, Investigational
IndoprofenIndoprofen may decrease the diuretic activities of Bumetanide.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Bumetanide is combined with Indoramin.Withdrawn
INNO-206The risk or severity of adverse effects can be increased when Bumetanide is combined with INNO-206.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Bumetanide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Bumetanide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Bumetanide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Bumetanide.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bumetanide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Bumetanide.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Bumetanide is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Bumetanide is combined with Isocarboxazid.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Bumetanide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Bumetanide is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Bumetanide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bumetanide.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bumetanide is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the diuretic activities of Bumetanide.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Bumetanide.Investigational
IvabradineBumetanide may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Kanamycin.Approved, Vet Approved
KebuzoneKebuzone may decrease the diuretic activities of Bumetanide.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Bumetanide.Approved
KetoprofenKetoprofen may decrease the diuretic activities of Bumetanide.Approved, Vet Approved
KetorolacKetorolac may decrease the diuretic activities of Bumetanide.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Bumetanide.Approved
LacidipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Lacidipine.Approved
LeflunomideLeflunomide may decrease the diuretic activities of Bumetanide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Levobupivacaine.Approved
LevodopaBumetanide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bumetanide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bumetanide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Bumetanide is combined with Levosimendan.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Bumetanide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Bumetanide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Bumetanide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bumetanide.Approved, Investigational
LisofyllineLisofylline may decrease the diuretic activities of Bumetanide.Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Bumetanide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Bumetanide.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Lofexidine.Approved, Investigational
LornoxicamLornoxicam may decrease the diuretic activities of Bumetanide.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide.Approved
LoxoprofenLoxoprofen may decrease the diuretic activities of Bumetanide.Approved
LumiracoxibLumiracoxib may decrease the diuretic activities of Bumetanide.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Bumetanide.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Bumetanide.Approved, Investigational
MasoprocolMasoprocol may decrease the diuretic activities of Bumetanide.Approved
ME-609ME-609 may increase the hypokalemic activities of Bumetanide.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Bumetanide.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Bumetanide.Approved
Mefenamic acidMefenamic acid may decrease the diuretic activities of Bumetanide.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Bumetanide.Vet Approved
MeloxicamMeloxicam may decrease the diuretic activities of Bumetanide.Approved, Vet Approved
MesalazineMesalazine may decrease the diuretic activities of Bumetanide.Approved
MetamizoleMetamizole may decrease the diuretic activities of Bumetanide.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Bumetanide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Bumetanide.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Bumetanide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Bumetanide.Approved
MethotrexateThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bumetanide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Bumetanide is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Bumetanide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Metipranolol.Approved
MetocurineBumetanide may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideBumetanide may decrease the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Bumetanide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bumetanide.Approved, Investigational
MetrizamideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Metrizamide.Approved
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Bumetanide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Bumetanide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bumetanide.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Bumetanide.Approved, Investigational
MivacuriumBumetanide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineMizoribine may decrease the diuretic activities of Bumetanide.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Bumetanide.Approved
MometasoneMometasone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Bumetanide.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Bumetanide.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Bumetanide.Approved
NabiloneThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the diuretic activities of Bumetanide.Approved
NadololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nadolol.Approved
NafamostatNafamostat may decrease the diuretic activities of Bumetanide.Investigational
NaftifineNaftifine may decrease the diuretic activities of Bumetanide.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Bumetanide.Approved
NaproxenNaproxen may decrease the diuretic activities of Bumetanide.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Bumetanide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Bumetanide.Investigational
NCX 4016NCX 4016 may decrease the diuretic activities of Bumetanide.Investigational
NeamineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Neamine.Experimental
NebivololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nebivolol.Approved, Investigational
NeomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinBumetanide may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the diuretic activities of Bumetanide.Approved
NesiritideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nesiritide.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Netilmicin.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Bumetanide.Approved
NicorandilNicorandil may increase the hypotensive activities of Bumetanide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Bumetanide.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nilvadipine.Approved
NimesulideNimesulide may decrease the diuretic activities of Bumetanide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bumetanide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bumetanide.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the diuretic activities of Bumetanide.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bumetanide.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bumetanide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Bumetanide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Bumetanide.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Bumetanide is combined with Obinutuzumab.Approved
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Bumetanide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bumetanide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Bumetanide.Approved
OlopatadineOlopatadine may decrease the diuretic activities of Bumetanide.Approved
OlsalazineOlsalazine may decrease the diuretic activities of Bumetanide.Approved
OmapatrilatBumetanide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Bumetanide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Bumetanide.Approved
OrgoteinOrgotein may decrease the diuretic activities of Bumetanide.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ouabain.Approved
OxaprozinOxaprozin may decrease the diuretic activities of Bumetanide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bumetanide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bumetanide.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Bumetanide.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Bumetanide is combined with Paclitaxel.Approved, Vet Approved
PancuroniumBumetanide may decrease the neuromuscular blocking activities of Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Bumetanide.Approved
ParecoxibParecoxib may decrease the diuretic activities of Bumetanide.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Paromomycin.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Bumetanide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Bumetanide.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Bumetanide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bumetanide.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Phenelzine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Bumetanide.Approved, Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Bumetanide.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Bumetanide.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Bumetanide.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the diuretic activities of Bumetanide.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Bumetanide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Bumetanide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Bumetanide is combined with Pipamperone.Approved
PipecuroniumBumetanide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Pirarubicin.Investigational
PirbuterolPirbuterol may increase the hypokalemic activities of Bumetanide.Approved
PirfenidonePirfenidone may decrease the diuretic activities of Bumetanide.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Bumetanide.Investigational
PiroxicamPiroxicam may decrease the diuretic activities of Bumetanide.Approved, Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Plicamycin.Approved, Withdrawn
PramipexoleThe risk or severity of adverse effects can be increased when Bumetanide is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Bumetanide.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Bumetanide.Approved, Nutraceutical
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Bumetanide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Bumetanide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Bumetanide.Experimental
PrimidonePrimidone may increase the hypotensive activities of Bumetanide.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Bumetanide.Approved
ProcaterolProcaterol may increase the hypokalemic activities of Bumetanide.Approved
PropacetamolPropacetamol may decrease the diuretic activities of Bumetanide.Approved
PropofolThe risk or severity of adverse effects can be increased when Bumetanide is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Bumetanide.Approved, Investigational
PTC299PTC299 may decrease the diuretic activities of Bumetanide.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Puromycin.Experimental
PyrantelBumetanide may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Bumetanide.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Bumetanide.Approved
RapacuroniumBumetanide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bumetanide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Bumetanide.Approved, Investigational
RescinnamineBumetanide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Bumetanide.Approved
ResveratrolResveratrol may decrease the diuretic activities of Bumetanide.Experimental, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ribostamycin.Approved
RimexoloneRimexolone may increase the hypokalemic activities of Bumetanide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Bumetanide is combined with Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Bumetanide is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Bumetanide.Approved
RocuroniumBumetanide may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the diuretic activities of Bumetanide.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Bumetanide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sacubitril.Approved
SalbutamolSalbutamol may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
SalicylamideSalicylamide may decrease the diuretic activities of Bumetanide.Approved
Salicylic acidSalicylic acid may decrease the diuretic activities of Bumetanide.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Bumetanide.Approved
SalsalateSalsalate may decrease the diuretic activities of Bumetanide.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Bumetanide.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Bumetanide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastSeratrodast may decrease the diuretic activities of Bumetanide.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sevoflurane.Approved, Vet Approved
SisomicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sisomicin.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Bumetanide.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Bumetanide.Approved
SP1049CThe risk or severity of adverse effects can be increased when Bumetanide is combined with SP1049C.Investigational
SpectinomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Spectinomycin.Approved, Vet Approved
SpiraprilBumetanide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bumetanide.Approved
SRT501SRT501 may decrease the diuretic activities of Bumetanide.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Bumetanide is combined with Streptokinase.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Streptomycin.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Streptozocin.Approved
SuccinylcholineBumetanide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bumetanide.Approved, Investigational
SulfasalazineSulfasalazine may decrease the diuretic activities of Bumetanide.Approved
SulindacSulindac may decrease the diuretic activities of Bumetanide.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Bumetanide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sulpiride.Approved
SuprofenSuprofen may decrease the diuretic activities of Bumetanide.Approved, Withdrawn
TamsulosinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Bumetanide.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Bumetanide is combined with Telmisartan.Approved, Investigational
TemocaprilBumetanide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamTenoxicam may decrease the diuretic activities of Bumetanide.Approved
TepoxalinTepoxalin may decrease the diuretic activities of Bumetanide.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Bumetanide.Approved
TeriflunomideTeriflunomide may decrease the diuretic activities of Bumetanide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Bumetanide.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Bumetanide.Investigational
ThiopentalThiopental may increase the hypotensive activities of Bumetanide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Thioridazine.Approved
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Bumetanide.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Bumetanide.Approved
TinoridineTinoridine may decrease the diuretic activities of Bumetanide.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Bumetanide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Bumetanide.Approved
TobramycinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tobramycin.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Bumetanide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Bumetanide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Bumetanide.Approved
TolmetinTolmetin may decrease the diuretic activities of Bumetanide.Approved
TopiramateBumetanide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bumetanide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bumetanide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bumetanide.Approved
TranilastTranilast may decrease the diuretic activities of Bumetanide.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Bumetanide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Bumetanide.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the diuretic activities of Bumetanide.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Bumetanide.Withdrawn
TubocurarineBumetanide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the diuretic activities of Bumetanide.Investigational, Withdrawn
ValrubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Valrubicin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bumetanide.Approved, Investigational
VecuroniumBumetanide may decrease the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Bumetanide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Bumetanide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Bumetanide.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Bumetanide.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the diuretic activities of Bumetanide.Approved
ZileutonZileuton may decrease the diuretic activities of Bumetanide.Approved, Investigational, Withdrawn
ZomepiracZomepirac may decrease the diuretic activities of Bumetanide.Withdrawn
ZorubicinThe risk or severity of adverse effects can be increased when Bumetanide is combined with Zorubicin.Experimental
Food Interactions
  • Take with food to reduce irritation.
References
Synthesis Reference

Felt, P.W.; US. Patent 3,634,583; January 11, 1972; assigned to Lovens Kemiske Fabrik
Produktionsaktieselskab, Denmark.

General ReferencesNot Available
External Links
ATC CodesC03EB02C03CB02C03CA02
AHFS Codes
  • 40:28.08
PDB EntriesNot Available
FDA labelDownload (206 KB)
MSDSDownload (72.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier-0.6636
Caco-2 permeable-0.6492
P-glycoprotein substrateNon-substrate0.509
P-glycoprotein inhibitor INon-inhibitor0.8765
P-glycoprotein inhibitor IINon-inhibitor0.8103
Renal organic cation transporterNon-inhibitor0.8966
CYP450 2C9 substrateNon-substrate0.6368
CYP450 2D6 substrateNon-substrate0.7656
CYP450 3A4 substrateNon-substrate0.6059
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7344
Ames testNon AMES toxic0.6794
CarcinogenicityNon-carcinogens0.7294
BiodegradationNot ready biodegradable0.9837
Rat acute toxicity1.8148 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9319
hERG inhibition (predictor II)Non-inhibitor0.8591
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
  • Validus pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Sandoz inc
Packagers
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous.25 mg/mL
Injection, solutionIntramuscular; Intravenous.25 mg/mL
Injection, solutionIntravenous.25 mg/mL
TabletOral.5 mg/1
TabletOral1 mg/1
TabletOral2 mg/1
TabletOral2 mg
TabletOral1 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Bumex 2 mg tablet1.65USD tablet
Bumetanide 2 mg tablet1.04USD tablet
Bumex 1 mg tablet0.98USD tablet
Bumex 0.5 mg tablet0.7USD tablet
Bumetanide 1 mg tablet0.51USD tablet
Bumetanide 0.5 mg tablet0.38USD tablet
Bumetanide 0.25 mg/ml vial0.25USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point230-231Felt, P.W.; US. Patent 3,634,583; January 11, 1972; assigned to Lovens Kemiske Fabrik Produktionsaktieselskab, Denmark.
water solubility>20 mg/mL (in base)Not Available
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0257 mg/mLALOGPS
logP3.44ALOGPS
logP2.42ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.69ChemAxon
pKa (Strongest Basic)2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.72 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity95.78 m3·mol-1ChemAxon
Polarizability37.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylethers
Direct ParentDiphenylethers
Alternative Parents
Substituents
  • Diphenylether
  • Diaryl ether
  • Aminobenzenesulfonamide
  • Benzenesulfonamide
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Phenylalkylamine
  • Substituted aniline
  • Benzoyl
  • Secondary aliphatic/aromatic amine
  • Aniline
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Thakker RV: Chloride channels in renal disease. Adv Nephrol Necker Hosp. 1999;29:289-98. [PubMed:10561751 ]
  2. Karolyi L, Koch MC, Grzeschik KH, Seyberth HW: The molecular genetic approach to "Bartter's syndrome". J Mol Med (Berl). 1998 Apr;76(5):317-25. [PubMed:9587066 ]
  3. Thakker RV: The role of renal chloride channel mutations in kidney stone disease and nephrocalcinosis. Curr Opin Nephrol Hypertens. 1998 Jul;7(4):385-8. [PubMed:9690036 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Long P, Mercer A, Begum R, Stephens GJ, Sihra TS, Jovanovic JN: Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37. doi: 10.1074/jbc.M805322200. Epub 2009 Jan 13. [PubMed:19141616 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A2
Uniprot ID:
P55011
Molecular Weight:
131445.825 Da
References
  1. Panet R, Marcus M, Atlan H: Overexpression of the Na(+)/K(+)/Cl(-) cotransporter gene induces cell proliferation and phenotypic transformation in mouse fibroblasts. J Cell Physiol. 2000 Jan;182(1):109-18. [PubMed:10567922 ]
  2. Evans RL, Park K, Turner RJ, Watson GE, Nguyen HV, Dennett MR, Hand AR, Flagella M, Shull GE, Melvin JE: Severe impairment of salivation in Na+/K+/2Cl- cotransporter (NKCC1)-deficient mice. J Biol Chem. 2000 Sep 1;275(35):26720-6. [PubMed:10831596 ]
  3. Wall SM, Fischer MP, Mehta P, Hassell KA, Park SJ: Contribution of the Na+-K+-2Cl- cotransporter NKCC1 to Cl- secretion in rat OMCD. Am J Physiol Renal Physiol. 2001 May;280(5):F913-21. [PubMed:11292635 ]
  4. Akar F, Jiang G, Paul RJ, O'Neill WC: Contractile regulation of the Na(+)-K(+)-2Cl(-) cotransporter in vascular smooth muscle. Am J Physiol Cell Physiol. 2001 Aug;281(2):C579-84. [PubMed:11443057 ]
  5. Jiang G, Klein JD, O'Neill WC: Growth factors stimulate the Na-K-2Cl cotransporter NKCC1 through a novel Cl(-)-dependent mechanism. Am J Physiol Cell Physiol. 2001 Dec;281(6):C1948-53. [PubMed:11698253 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein kinase binding
Specific Function:
Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral Cl(-) exit in NaCl absorbing epithelia (By similarity). Isoform 4 has no transport activity.
Gene Name:
SLC12A4
Uniprot ID:
Q9UP95
Molecular Weight:
120648.73 Da
References
  1. Jean-Xavier C, Pflieger JF, Liabeuf S, Vinay L: Inhibitory postsynaptic potentials in lumbar motoneurons remain depolarizing after neonatal spinal cord transection in the rat. J Neurophysiol. 2006 Nov;96(5):2274-81. Epub 2006 Jun 28. [PubMed:16807348 ]
  2. Reid KH, Guo SZ, Iyer VG: Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Brain Res. 2000 May 2;864(1):134-7. [PubMed:10793196 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein kinase binding
Specific Function:
Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in neurons.
Gene Name:
SLC12A5
Uniprot ID:
Q9H2X9
Molecular Weight:
126182.49 Da
References
  1. Reid KH, Guo SZ, Iyer VG: Agents which block potassium-chloride cotransport prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats. Brain Res. 2000 May 2;864(1):134-7. [PubMed:10793196 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Pdz domain binding
Specific Function:
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO1. Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation.
Gene Name:
CFTR
Uniprot ID:
P13569
Molecular Weight:
168139.895 Da
References
  1. Reddy MM, Quinton PM: Bumetanide blocks CFTR GCl in the native sweat duct. Am J Physiol. 1999 Jan;276(1 Pt 1):C231-7. [PubMed:9886939 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Cheng HF, Wang JL, Zhang MZ, McKanna JA, Harris RC: Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest. 2000 Sep;106(5):681-8. [PubMed:10974021 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Hagenbuch B, Stieger B, Foguet M, Lubbert H, Meier PJ: Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10629-33. [PubMed:1961729 ]
  2. Platte HD, Honscha W, Schuh K, Petzinger E: Functional characterization of the hepatic sodium-dependent taurocholate transporter stably transfected into an immortalized liver-derived cell line and V79 fibroblasts. Eur J Cell Biol. 1996 May;70(1):54-60. [PubMed:8738419 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739 ]
  2. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Horz JA, Honscha W, Petzinger E: Bumetanide is not transported by the Ntcp or by the oatp: evidence for a third organic anion transporter in rat liver cells. Biochim Biophys Acta. 1996 Apr 19;1300(2):114-8. [PubMed:8652636 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23